We have advised Mural Oncology plc (NASDAQ: MURA) on its recent agreement with XRA 5 Corp, a wholly owned subsidiary of XOMA Royalty Corporation, to be acquired for a cash price of between $2.035 and $2.40 per share, using a first of its kind consideration structure for a public takeover in Ireland.

The team was led by Chris McLaughlin, David Vos (Corporate and M&A), Fintan Clancy (Tax) and Patrick Horan (Competition and Regulated Markets), and John Donald (Restructuring and Insolvency). The team included James Cotter, Andrea Bowdren, Susan O’Leary, Zara Murphy, Niamh McCarthy (Corporate and M&A), Jessica Lewis and Nicola Cavey (Tax), Lís O’Connor (Competition and Regulated Markets) and Kenneth Dixon (Restructuring and Insolvency).

For more on the agreement, please read this press release: Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share | Global News Wire